Brought to you by 
Pfizer develops Eyetech's Macugen
Dec 2002
Executive Summary
Pfizer and Eyetech Pharmaceuticals (develops drugs to reduce and prevent vision loss caused by eye disease) will jointly develop and commercialize Eyetech's Macugen (pegaptanib sodium) for treating age-related macular degeneration (AMD) and diabetic macular edema (DME).
Deal Industry
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- R+D and Marketing-Licensing
- Co-Promotion
- Includes Contract
- Product or Technology Swap
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Pfizer develops Eyetech's Macugen
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice